Eupraxia Pharmaceuticals reported new trial data showing EP-104GI improved esophagus tissue health and maintained remission ...

At week 12, the highest dosed patients achieved the best tissue response seen in the trial to date, with a near complete improvement in tissue health1- At lower doses, patients maintained the improvem ...

At week 12, the highest dosed patients achieved the best tissue response seen in the trial to date, with a near complete ...

Phathom Pharmaceuticals (NASDAQ: PHAT) reported Q4 sales of $57-$58 million, updated FY2025 revenue guidance to $174.5-$175.5 million.

We read with interest the article by Santacroce about personalised medicine in eosinophilic oesophagitis (EoE) and the ...

Apogee Therapeutics ( ($APGE) ) has provided an announcement. On January 6, 2026, Apogee Therapeutics reported positive interim results from a ...

Dupilumab, a fully human monoclonal antibody, inhibits the signaling of the interleukin 4 (IL-4) and IL-13 pathways.

AURORA, Colo., Oct. 08, 2025 (GLOBE NEWSWIRE) -- EnteroTrack LLC announced that the Centers for Medicare & Medicaid Services (CMS) is paying for the company’s Esophageal String Test ® (EST), marking a ...

Note: The U.S. Food and Drug Administration (FDA) does not approve supplements for safety or effectiveness. Talk to a healthcare professional about whether a supplement is the right fit for your ...

Patients with eosinophilic esophagitis (EoE) often describe the condition as painful, disruptive and frightening. The rare chronic disease causes inflammation of the esophagus, leading to abdominal ...

Researchers from Children's Hospital of Philadelphia (CHOP) and Children's Hospital Colorado have found that better control of chronic eosinophilic esophagitis (EoE)-associated inflammation during ...

Etokimab (I-Mab Biopharma), which is optimized for common IL-33 gene polymorphisms, has completed patient recruitment in its ...